Gliknik

Gliknik, Pfizer enter autoimmune disease licensing agreement

Monday, September 30, 2013

Gliknik, a privately-held biopharmaceutical company, has entered into an exclusive worldwide licensing agreement with Pfizer for GL-2045, Gliknik’s recombinant stradomer, a drug candidate that is designed to replace and improve on pooled human intravenous immunoglobulin (IVIG). GL-2045 has shown promising results in preclinical tests and is being developed as a potential treatment for a wide variety of autoimmune diseases, including those in which IVIG is clinically used.

[Read More]